Compare Gilead Sciences, Inc. (GILD) vs Vanguard S&P 500 ETF (VOO) Price & Performance

Gilead Sciences, Inc.Trade

Vanguard S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Vanguard S&P 500 ETF — how do they compare? Gilead Sciences, Inc. trades at $136.01 (market cap $163.51B), while Vanguard S&P 500 ETF trades at $689.59. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Vanguard S&P 500 ETF pays none, and Vanguard S&P 500 ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

	GILD	VOO
Market Cap	$163.51B	—
Sector	Health	Broad Market / Factor
52-Week High	$155.80	$698.29
52-Week Low	$108.22	$571.45
Enterprise Value	$178.05B	—
Dividend Yield	2.49%	—

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

Vanguard S&P 500 ETF

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

GILD

Kalshi launches betting markets on pharma trial outcomes and FDA drug approvals.Forbes · 4 hours agoNeutral View details →

VOO

Covered-call ETF XYLD caps gains for steady income but lags S&P 500 returns significantly.24/7 Wall Street · 1 day agoBearish Fed cuts forward guidance, boosting market volatility and focus on past inflation data.Seeking Alpha · 1 day agoNeutral State Street's SPYM ETF chosen for Trump Accounts, offering low-cost S&P 500 exposure for newborns.24/7 Wall Street · 1 day agoBullish View details →

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

About Vanguard S&P 500 ETF

VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.